Could selenoproteins be the key to fighting a tough breast cancer?

NCT ID NCT05817227

Recruiting now Knowledge-focused Sponsor: National Cancer Institute, Naples Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at proteins called selenoproteins in people with triple-negative breast cancer (TNBC), a hard-to-treat type. Researchers will measure these proteins in tumor samples and blood from 300 patients and 100 healthy women. The goal is to see if selenoproteins can help predict outcomes or serve as targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could identify new ways to predict or treat triple-negative breast cancer by targeting selenoproteins.
What could go wrong: This is an early observational study, not a treatment trial. It may not lead to direct therapies, and results may not apply to all breast cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Istituto Nazionale Tumori - Fondazione "G.Pascale", IRCCS
RECRUITING

Naples, Napoli, 80131, Italy
Istituto Nazionale Tumori Regina Elena
RECRUITING

Roma, Roma, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.